SCHEMBL30765656

SCHEMBL30765656

COC(=O)Cn1c(N2CCCCC2)cnc(N[C@H](CO[Si](C)(C)C(C)(C)C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.34
USP2 O75604 2/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
MCHR1 Q99705 1/20 0.31
LMNA P02545 2/20 0.30
ALDH1A1 P00352 2/20 0.30
NPSR1 Q6W5P4 1/20 0.30
PRKDC P78527 1/20 0.30
KDM4E B2RXH2 2/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765626 0.94 USP2 (0.33) USP2POLBGAAMAPK1HTT
SCHEMBL30765754 0.84 MAPK1 (0.34) MAPK1
SCHEMBL30766072 0.76 SOS1 (0.39) GAAALDH1A1PRKDCKDM4EMAPT
SCHEMBL30765672 0.73 ALDH1A1 (0.33) KMT2APOLBGAAHTTHCRTR1
SCHEMBL30765748 0.72 SOS1 (0.40) KMT2AGAAMAPK1HTTLMNA
SCHEMBL30766079 0.71 TSHR (0.38) KMT2AGAALMNAALDH1A1MAPT
SCHEMBL30765645 0.71 MAPK1 (0.35) KMT2AUSP2MAPK1ALDH1A1TP53
SCHEMBL30766002 0.71 USP2 (0.37) KMT2AUSP2POLBGAAMAPK1
SCHEMBL30765729 0.69 ALDH1A1 (0.38) KMT2ALMNAALDH1A1NPSR1KDM4E
SCHEMBL31558557 0.64 POLB (0.37) KMT2AUSP2POLBGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed